PE20121076A1 - Composicion farmaceutica que comprende un analgesico y vitaminas - Google Patents

Composicion farmaceutica que comprende un analgesico y vitaminas

Info

Publication number
PE20121076A1
PE20121076A1 PE2012000146A PE2012000146A PE20121076A1 PE 20121076 A1 PE20121076 A1 PE 20121076A1 PE 2012000146 A PE2012000146 A PE 2012000146A PE 2012000146 A PE2012000146 A PE 2012000146A PE 20121076 A1 PE20121076 A1 PE 20121076A1
Authority
PE
Peru
Prior art keywords
pharmaceutical composition
analgesic
vitamins
composition including
lupus
Prior art date
Application number
PE2012000146A
Other languages
English (en)
Spanish (es)
Inventor
Mahmood Ahmed
James Myatt
Norton David
Dean Andrew Rivers
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39283563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20121076(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0625647A external-priority patent/GB0625647D0/en
Priority claimed from GB0707615A external-priority patent/GB0707615D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20121076A1 publication Critical patent/PE20121076A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
PE2012000146A 2006-12-21 2008-01-02 Composicion farmaceutica que comprende un analgesico y vitaminas PE20121076A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0625647A GB0625647D0 (en) 2006-12-21 2006-12-21 Compounds
GB0707615A GB0707615D0 (en) 2007-04-19 2007-04-19 Compounds

Publications (1)

Publication Number Publication Date
PE20121076A1 true PE20121076A1 (es) 2012-09-05

Family

ID=39283563

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000146A PE20121076A1 (es) 2006-12-21 2008-01-02 Composicion farmaceutica que comprende un analgesico y vitaminas
PE2008000023A PE20081398A1 (es) 2006-12-21 2008-01-02 Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1)

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008000023A PE20081398A1 (es) 2006-12-21 2008-01-02 Derivados de oxadiazol como agonistas del receptor sensible a 1-fosfato de esfingosina (s1p1)

Country Status (32)

Country Link
US (1) US8101775B2 (Direct)
EP (2) EP2091949B1 (Direct)
JP (1) JP5309034B2 (Direct)
KR (1) KR101495927B1 (Direct)
CN (1) CN103012390B (Direct)
AR (1) AR064452A1 (Direct)
AT (1) ATE509927T1 (Direct)
AU (1) AU2007336224B2 (Direct)
BR (1) BRPI0721127A2 (Direct)
CA (1) CA2673468C (Direct)
CL (1) CL2007003755A1 (Direct)
CR (2) CR10922A (Direct)
CY (2) CY1111702T1 (Direct)
DK (2) DK2206710T3 (Direct)
DO (1) DOP2009000133A (Direct)
EA (1) EA017406B1 (Direct)
ES (1) ES2389879T3 (Direct)
HR (2) HRP20110456T1 (Direct)
IL (1) IL199187A (Direct)
JO (1) JO2701B1 (Direct)
MA (1) MA30999B1 (Direct)
MX (1) MX2009006882A (Direct)
MY (2) MY156822A (Direct)
NO (1) NO20092385L (Direct)
NZ (1) NZ577387A (Direct)
PE (2) PE20121076A1 (Direct)
PL (2) PL2091949T3 (Direct)
PT (2) PT2091949E (Direct)
SG (1) SG177914A1 (Direct)
SI (2) SI2206710T1 (Direct)
TW (1) TWI393564B (Direct)
WO (1) WO2008074821A1 (Direct)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2003132B1 (en) 2006-04-03 2014-03-05 Astellas Pharma Inc. Oxadiazole derivatives as S1P1 agonists
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
TWI408137B (zh) * 2007-04-19 2013-09-11 Glaxo Group Ltd 經取代之二唑衍生物、其醫藥用途及醫藥組合物
GB0807910D0 (en) 2008-04-30 2008-06-04 Glaxo Group Ltd Compounds
US8796318B2 (en) 2008-05-14 2014-08-05 The Scripps Research Institute Modulators of sphingosine phosphate receptors
WO2009151621A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
WO2009151626A1 (en) * 2008-06-13 2009-12-17 Arena Pharmaceuticals, Inc. Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
US20100010053A1 (en) 2008-06-20 2010-01-14 Jose Luis Castro Pineiro Compounds
KR101608108B1 (ko) * 2008-07-23 2016-03-31 노파르티스 아게 스핑고신 1 포스페이트 수용체 조절제 및 근육 염증을 치료하기 위한 그의 용도
US8580841B2 (en) 2008-07-23 2013-11-12 Arena Pharmaceuticals, Inc. Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders
PL2342205T3 (pl) * 2008-08-27 2016-12-30 Podstawione tricykliczne pochodne kwasowe jako antagoniści receptora S1P1 użyteczni w leczeniu zaburzeń autoimmunologicznych i zapalnych
AU2009327133B2 (en) * 2008-12-18 2016-04-14 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
EP2202232A1 (en) * 2008-12-26 2010-06-30 Laboratorios Almirall, S.A. 1,2,4-oxadiazole derivatives and their therapeutic use
EP2241558A1 (en) * 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
GB0910667D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
GB0910689D0 (en) * 2009-06-19 2009-08-05 Glaxo Wellcome Mfg Pte Ltd Novel compounds
WO2011005295A1 (en) * 2009-06-24 2011-01-13 Arena Pharmaceuticals, Inc. Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto
UA107360C2 (en) * 2009-08-05 2014-12-25 Biogen Idec Inc Bicyclic aryl sphingosine 1-phosphate analogs
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
RS57253B2 (sr) 2009-11-13 2024-10-31 Receptos Llc Selektivni modulatori fingozin 1-fosfat receptora i postupci asimetrične sinteze
WO2011072488A1 (en) * 2009-12-18 2011-06-23 Glaxo Group Limited Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate 1 (s1p1) receptor agonists
CN108558740B (zh) 2010-01-27 2021-10-19 艾尼纳制药公司 S1p1受体调节剂及其盐的制备方法
EP2542554B1 (en) 2010-03-03 2015-11-04 Arena Pharmaceuticals, Inc. Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
CN103119038B (zh) 2010-04-23 2016-05-04 百时美施贵宝公司 作为1-磷酸鞘氨醇1受体激动剂的4-(5-异噁唑基或5-吡唑基-1，2，4-噁二唑基-3-基)扁桃酰胺
WO2012040532A1 (en) 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
MY163274A (en) 2011-02-07 2017-08-30 Biogen Ma Inc S1p modulating agents
EP2706999B1 (en) 2011-05-13 2019-08-28 Celgene International II Sàrl Selective heterocyclic sphingosine 1 phosphate receptor modulators
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201202027D0 (en) * 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
KR102883123B1 (ko) 2015-06-22 2025-11-10 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염
US11192886B2 (en) * 2016-07-22 2021-12-07 Medshine Discovery Inc. S1P1 agonist and application thereof
KR102408814B1 (ko) * 2016-09-29 2022-06-14 리셉토스 엘엘씨 루푸스를 치료하기 위한 화합물 및 방법
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2981521T3 (es) 2017-02-16 2024-10-09 Arena Pharm Inc Compuestos y procedimientos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales
WO2019236757A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN110627778B (zh) * 2018-06-25 2023-01-24 中国科学院上海药物研究所 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用
US11555015B2 (en) 2018-09-06 2023-01-17 Arena Pharmaceuticals, Inc. Compounds useful in the treatment of autoimmune and inflammatory disorders
AU2020372647A1 (en) 2019-10-31 2022-06-16 Idorsia Pharmaceuticals Ltd Combination of a CXCR7 antagonist with an S1P1 receptor modulator
KR102576671B1 (ko) 2019-12-03 2023-09-11 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물
JP7738001B2 (ja) * 2020-02-11 2025-09-11 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物的に活性な環状アミン化合物
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2025083549A1 (en) 2023-10-16 2025-04-24 Sun Pharma Advanced Research Company Limited Methods and combinations of inhibitors of il-23 pathway and modulators of s1p signaling pathway for the treatment of autoimmune disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3939238A1 (de) 1989-11-28 1991-05-29 Bayer Ag Heterocyclisch substituierte acrylsaeureester
DE4002466A1 (de) 1990-01-28 1991-10-10 Bayer Ag Substituierte 2-(6-(pyrimidinyl)-indo-l-yl)-acrylsaeureester
US5523312A (en) 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
DE19620041A1 (de) 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
AU2004240586A1 (en) 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1670463A2 (en) 2003-10-01 2006-06-21 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
JP4773972B2 (ja) 2003-12-17 2011-09-14 メルク・シャープ・エンド・ドーム・コーポレイション Ｓ１Ｐ（Ｅｄｇ）受容体作働薬としての（３，４−ジ置換）プロパンカルボン酸
JP5315611B2 (ja) 2004-06-23 2013-10-16 小野薬品工業株式会社 Ｓ１ｐ受容体結合能を有する化合物およびその用途
CA2583681A1 (en) 2004-10-22 2006-05-04 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as s1p receptor agonists
KR101377790B1 (ko) 2005-02-25 2014-03-27 오노 야꾸힝 고교 가부시키가이샤 인돌 화합물 및 이의 용도
PT1863474E (pt) 2005-03-23 2009-01-20 Actelion Pharmaceuticals Ltd Novos derivados de tiofeno como agonistas dos receptores 1 de esfingosina-1-fosfato
DE602006015297D1 (de) 2005-04-22 2010-08-19 Daiichi Sankyo Co Ltd 3-azetidincarbonsäure-derivate zur verwendung als immunsuppressiva
JP2008545767A (ja) 2005-06-08 2008-12-18 ノバルティス アクチエンゲゼルシャフト 多環式オキサジアゾールまたはイソキサゾールおよびｓｉｐ受容体リガンドとしてのそれらの使用
EP1917240A1 (en) 2005-08-23 2008-05-07 Irm Llc Immunosuppressant compounds and compositions
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
JP2007262009A (ja) 2006-03-29 2007-10-11 Dai Ichi Seiyaku Co Ltd ヘテロアリール低級カルボン酸誘導体
EP2003132B1 (en) * 2006-04-03 2014-03-05 Astellas Pharma Inc. Oxadiazole derivatives as S1P1 agonists
PL2069336T3 (pl) 2006-09-07 2013-05-31 Idorsia Pharmaceuticals Ltd Pochodne pirydyn-4-ylu jako środki immunomodulujące
JO2701B1 (en) 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
TWI408137B (zh) * 2007-04-19 2013-09-11 Glaxo Group Ltd 經取代之二唑衍生物、其醫藥用途及醫藥組合物

Also Published As

Publication number Publication date
EP2091949B1 (en) 2011-05-18
TW200843736A (en) 2008-11-16
MA30999B1 (fr) 2009-12-01
CR10922A (es) 2009-08-12
MY156822A (en) 2016-03-31
IL199187A (en) 2015-04-30
DOP2009000133A (es) 2009-08-15
PT2091949E (pt) 2011-07-13
EP2206710A1 (en) 2010-07-14
JP5309034B2 (ja) 2013-10-09
HK1130255A1 (en) 2009-12-24
NO20092385L (no) 2009-08-24
CL2007003755A1 (es) 2008-08-22
ATE509927T1 (de) 2011-06-15
EP2206710B1 (en) 2012-07-04
KR20090092290A (ko) 2009-08-31
CY1113131T1 (el) 2016-04-13
CY1111702T1 (el) 2015-10-07
AU2007336224B2 (en) 2013-01-10
CN103012390A (zh) 2013-04-03
MX2009006882A (es) 2009-07-03
KR101495927B1 (ko) 2015-02-25
CR20140316A (es) 2014-08-20
CN103012390B (zh) 2015-08-26
DK2091949T3 (da) 2011-07-18
TWI393564B (zh) 2013-04-21
HK1140761A1 (en) 2010-10-22
SG177914A1 (en) 2012-02-28
DK2206710T3 (da) 2012-08-27
ES2389879T3 (es) 2012-11-02
US20100113796A1 (en) 2010-05-06
EP2091949A1 (en) 2009-08-26
IL199187A0 (en) 2010-03-28
AR064452A1 (es) 2009-04-01
JP2010513397A (ja) 2010-04-30
PT2206710E (pt) 2012-09-10
SI2206710T1 (sl) 2012-10-30
EA200970612A1 (ru) 2009-10-30
WO2008074821A1 (en) 2008-06-26
NZ577387A (en) 2012-01-12
EA017406B1 (ru) 2012-12-28
MY148470A (en) 2013-04-30
PL2091949T3 (pl) 2011-10-31
BRPI0721127A2 (pt) 2014-03-11
CA2673468C (en) 2015-06-02
AU2007336224A1 (en) 2008-06-26
SI2091949T1 (sl) 2011-08-31
US8101775B2 (en) 2012-01-24
PE20081398A1 (es) 2008-11-19
HRP20110456T1 (hr) 2011-07-31
JO2701B1 (en) 2013-03-03
CA2673468A1 (en) 2008-06-26
HRP20120685T1 (hr) 2012-09-30
PL2206710T3 (pl) 2012-11-30

Similar Documents

Publication Publication Date Title
PE20121076A1 (es) Composicion farmaceutica que comprende un analgesico y vitaminas
CL2008000422A1 (es) El compuesto acido 4-[4-(2-adamantilcarbamoil)-5-terbutilpirazol-1-il]-benzoico; composicion farmaceutica; su uso como inhibidor de 11bhsd1, util en el tratamiento de la diabetes tipo 2 y la obesidad.
Tsai et al. Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs
BRPI0512624A (pt) compostos heteroarila e fenilsulfamoìla substituìdos
PE20091456A1 (es) Nuevas formas cristalinas de acido 4-[4-(2-adamantilcarbamoil)-5-tert-butil-pirazol-1-il]benzoico- 471
CL2007001700A1 (es) Formas cristalinas 2 y 3 del acido (trans-4-{4-((5-(3,4-difluorofenil)amino}-1,3,4-oxadiazol-2-il)carbonil)amino}fenil)ciclohexil)acetico;composicion farmaceutica que comprende a dicho compuesto;y su uso para inhibir la actividad de diacilglicerol aciltransferasa (dgat1)
Shim The study on the elderly homodialysis patients' transition of health condition and health-related quality of life
Joo Work, care or leisure?-the effects of gender and education on time allocation of full-time working parents
Kim et al. Compressive Strength Characteristics of Non-Cement Composition Added with Limestone Powder
Chon et al. Extraarticular Pan-peri-meniscal Synovial Chondroma Suspected as a Ganglion Cyst-Case Report
Li et al. Antistatic effects of silver plated carbon nanotubes on polymer fiber
In et al. Mass Production of Physiological Active Compounds by Bioconversion using Bioreactor
Jin et al. A study on the relationship between patient clothes and hospital satisfaction
Lee A Study on the Motivation for the Participation in Video UCC Production and Its Effects
Hong et al. Experimental study for self-healing performance of concrete using admixture
Jeong Sepsis Developed from an Odontogenic Infection
Kim et al. Chronic Lateral Ankle Instability Effect of Associated Os Subfibulare on Ligament Reconstruction
Choi et al. A Study on the Applications of Herba Menthae Mainly Blended Prescription in Dongeuibogam
Beom et al. Two cases of green nail syndrome
Yeon et al. A case of acneiform eruption and paronychia occurring after use of erlotinib (Tarceva®)
Kim et al. Factors Affecting the Preparation for Later Life According to Age in Production Workers
Kim et al. Early Clinical Outcomes of Total Ankle Arthroplasty Using Hintegra
Koh et al. The combination treatment of angiotensin II receptor antagonist and aldosterone receptor antagonist modulates matrix metalloproteinase-2 expression and activity in infarcted myocardium
Debi et al. Arthroscopic Reconstruction of the Anterior Cruciate Ligament-Prospective Study
Choe et al. The Antimicrobial effect of Cotton Fabric by Self-manifestation Natural Antimicrobial agent Treatment

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed